Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Catching new targets in metabolic disease with a zebrafish.
Curr. Opin. Pharmacol. 37, 41-50 (2017)
Traditionally, the development of novel therapeutics for metabolic diseases has relied mainly on high-throughput screening using biochemical or cell-based assays. While this approach represents a driving force in drug discovery, there is also a need to perform large-scale screens without disrupting inter-organ communication and tissue architecture, essential components for understanding the complexity of metabolic regulation and the identification of small molecules with appropriate biological activities in vivo. Hence, the zebrafish Danio rerio is gaining popularity in metabolic research and drug discovery, as this animal model allows screening of small molecules in the context of the whole-organism. Moreover, the zebrafish exhibits conserved function of the pancreas, liver and adipose tissue, which can be leveraged to identify novel targets in metabolic regulation, as well as to study the role of conserved genes associated with the risk of metabolic diseases in humans. Here we highlight recent advances in the identification of targets in metabolic regulation using the zebrafish as a model.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
5.363
1.482
23
25
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Review
Keywords
Beta-cell Mass; Body-fat Distribution; Genetic Screen; Adipose-tissue; Liver-disease; Glucose-homeostasis; Danio-rerio; In-vivo; Regeneration; Pancreas
Language
english
Publication Year
2017
HGF-reported in Year
2017
ISSN (print) / ISBN
1471-4892
e-ISSN
1471-4973
Journal
Current opinion in pharmacology
Quellenangaben
Volume: 37,
Pages: 41-50
Publisher
Elsevier
Publishing Place
London
Reviewing status
Peer reviewed
Institute(s)
Institute of Pancreatic Islet Research (IPI)
POF-Topic(s)
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502600-010
WOS ID
WOS:000419423700009
Scopus ID
85028707862
PubMed ID
28888214
Erfassungsdatum
2017-09-20